Observational studyFrontiers in endocrinology2026
iGlarlixi for the simplification of more complex insulin regimens in type 2 diabetes patients with good glycaemic control.
Observational study in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Knowledge on insulin treatment simplification with fixed ratio combinations (e.g. iGlarLixi, combination of insulin glargine and lixisenatide) is limited. Our aim was to examine long-term effectiveness and safety of treatment simplification with iGlarLixi in type 2 diabetes. Materials and methods: We report a single-centre, observational study of n=51 type 2 diabetes patients with HbA1c ≤ 7.5% (58 mmol/mol) who switched from basal-bolus or premixed insulins to iGlarLixi in 01/JAN/2017-30/JUN/2023 with up to 61-month follow-up. Outcomes were trajectories of HbA1c, BMI, insulin need, and risk of incident hypoglycaemia based on mixed linear models. Results: Participants (53% women) were 69.4 years old, BMI was 30.6 kg/m Conclusions: Simplification of complex regimens with iGlarLixi in patients with good glycaemic control maintains glycaemic control with weight loss, reduced risk of hypoglycaemia, and lower insulin dose over 42 months.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.